Filter By Category
Archives
Share on -
AXATILIMAB
Generic Name: AXATILIMAB
ABSTRACT -
Axatilimab is a colony-stimulating factor 1 receptor (CSF-1R)-blocking monoclonal antibody used where approved for chronic graft-versus-host disease after failure of prior systemic therapy. As a monoclonal antibody, it does not have a meaningful small-molecule molecular formula. The representation above shows an antibody schematic.
This document is for structured API information only. It is not a prescribing guide. Clinical use, if any, must follow the approved local label, trial protocol, and specialist medical supervision.
DOSAGE-
- Dosage should be determined only by a qualified healthcare professional.
- Use only according to the approved local product label for the specific indication.
- Dose, infusion rate, premedication, and monitoring may differ by body weight, response, and toxicity.
- Do not change, stop, or restart treatment without transplant or immunology specialist supervision.
SIDE EFFECTS-
Possible side effects and safety concerns include:
- Infusion-related reactions including chills, fever, flushing, rash, dyspnea, or hypotension
- Infections, fatigue, headache, cough, diarrhea, nausea, or shortness of breath
- Elevated liver enzymes, pancreatic enzymes, creatine kinase, calcium, or alkaline phosphatase
- Anemia, low phosphate, musculoskeletal pain, or laboratory abnormalities
- Underlying chronic graft-versus-host disease may overlap with treatment effects
ALLERGIC REACTIONS -
Hypersensitivity to Axatilimab or related compounds/products may occur. Symptoms may include:
- Immediate urticaria, itching, flushing, or generalized rash
- Facial, lip, tongue, or throat swelling
- Wheezing, chest tightness, or breathing difficulty
- Dizziness, fainting, severe hypotension, or collapse
- Anaphylaxis, although uncommon, requires emergency medical treatment
Important: Patients who develop an allergic reaction to Axatilimab should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS-
Axatilimab may interact with certain medicines, biologics, vaccines, protocols, or clinical conditions. Caution is needed with:
- Other immunosuppressants, corticosteroids, and infection prophylaxis medicines require careful coordination.
- Live vaccines should generally be avoided or deferred unless a specialist approves.
- Concomitant hepatotoxic or pancreatitis-associated medicines may increase monitoring needs.
- Patients should report all medicines, supplements, vaccines, and herbal products.
Patients should inform healthcare providers about all prescription medicines, over-the-counter medicines, herbal products, vaccines, and supplements they are using.
PREAUTIONS–
- Monitor for infusion reactions during and after administration.
- Monitor liver enzymes, pancreatic enzymes, blood counts, infection symptoms, and disease response.
- Use caution in patients with uncontrolled infection or severe organ dysfunction.
- Pregnancy and lactation require individualized specialist review.
WARNINGS –
- Serious infusion-related or hypersensitivity reactions can occur.
- Infection risk may increase in immunocompromised patients.
- Laboratory abnormalities involving liver, pancreas, muscle, calcium, and phosphate require monitoring.
- Keep out of reach of children.
Share on -
. Developed by